The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Staging and Functional Characterization of Pheochromocytoma and Paraganglioma by 18F-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography
Open accessAbstract
BACKGROUND: Pheochromocytomas and paragangliomas (PPGLs) are rare tumors of the adrenal medulla and extra-adrenal sympathetic chromaffin tissues; their anatomical and functional imaging are critical to guiding treatment decisions. This study aimed to compare the sensitivity and specificity of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography ((18)F-FDG PET/CT) for tumor localization and staging of PPGLs with that of conventional imaging by [(123)I]-metaiodobenzylguanidine single photon emission CT ((123)I-MIBG SPECT), CT, and magnetic resonance imaging (MRI). METHODS: A total of 216 patients (106 men, 110 women, aged 45.2 ± 14.9 years) with suspected PPGL underwent CT or MRI, (18)F-FDG PET/CT, and (123)I-MIBG SPECT/CT. Sensitivity and specificity were measured as endpoints and compared by the McNemar test, using two-sided P values only. RESULTS: Sixty (28%) of patients had nonmetastatic PPGL, 95 (44%) had metastatic PPGL, and 61 (28%) were PPGL negative. For nonmetastatic tumors, the sensitivity of (18)F-FDG was similar to that of (123)I-MIBG but less than that of CT/MRI (sensitivity of (18)F-FDG = 76.8%; of (123)I-MIBG = 75.0%; of CT/MRI = 95.7%; (18)F-FDG vs (123)I-MIBG: difference = 1.8%, 95% confidence interval [CI] = -14.8% to 14.8%, P = .210; (18)F-FDG vs CT/MRI: difference = 18.9%, 95% CI = 9.4% to 28.3%, P < .001). The specificity was 90.2% for (18)F-FDG, 91.8% for (123)I-MIBG, and 90.2% for CT/MRI. (18)F-FDG uptake was higher in succinate dehydrogenase complex- and von Hippel-Lindau syndrome-related tumors than in multiple endocrine neoplasia type 2 (MEN2) related tumors. For metastases, sensitivity was greater for (18)F-FDG and CT/MRI than for (123)I-MIBG (sensitivity of (18)F-FDG = 82.5%; of (123)I-MIBG = 50.0%; of CT/MRI = 74.4%; (18)F-FDG vs (123)I-MIBG: difference = 32.5%, 95% CI = 22.3% to 42.5%, P < .001; CT/MRI vs (123)I-MIBG: difference = 24.4%, 95% CI = 11.3% to 31.6%, P < .001). For bone metastases, (18)F-FDG was more sensitive than CT/MRI (sensitivity of (18)F-FDG = 93.7%; of CT/MRI = 76.7%; difference = 17.0%, 95% CI = 4.9% to 28.5%, P = .013). CONCLUSIONS: Compared with (123)I-MIBG SPECT and CT/MRI, both considered gold standards for PPGL imaging, metastases were better detected by (18)F-FDG PET. (18)F-FDG PET provides a high specificity in patients with a biochemically established diagnosis of PPGL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Lenders, J. W., Eisenhofer, G., Mannelli, M., & Pacak, K. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67139-5 · Cited by 1,524
Self-citationGerm-Line Mutations in Nonsyndromic Pheochromocytoma
Neumann, H. P. H., Bausch, B., McWhinney, S. R., Bender, B. U., Gimm, O., Franke, G., Schipper, J., Klisch, J., Altehoefer, C., Zerres, K., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020152 · Cited by 1,367
Biochemical Diagnosis of Pheochromocytoma: Which Test Is Best?
Lenders, J. W. M., Pacak, K., Walther, M. M., Linehan, W. M., Mannelli, M., Friberg, P., Keiser, H. R., Goldstein, D. S., & Eisenhofer, G. (2002) · JAMA · doi:10.1001/jama.287.11.1427 · Cited by 1,134
Self-citationNeumann, H. P. H. (2004) · JAMA · doi:10.1001/jama.292.8.943 · Cited by 893
SDHA is a tumor suppressor gene causing paraganglioma
Burnichon, N., Brière, J.-J., Libé, R., Vescovo, L., Rivière, J., Tissier, F., Jouanno, E., Jeunemaitre, X., Bénit, P., Tzagoloff, A., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq206 · Cited by 650
(1986) · CERN Document Server (European Organization for Nuclear Research) · Cited by 583
A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas
Dahia, P. L. M., Ross, K. N., Wright, M. E., Hayashida, C. Y., Santagata, S., Barontini, M., Kung, A. L., Sanso, G., Powers, J. F., Tischler, A. S., et al. (2005) · PLoS Genetics · doi:10.1371/journal.pgen.0010008 · Cited by 443
Germline mutations in TMEM127 confer susceptibility to pheochromocytoma
Qin, Y., Yao, L., King, E. E., Buddavarapu, K., Lenci, R. E., Chocron, E. S., Lechleiter, J. D., Sass, M., Aronin, N., Schiavi, F., et al. (2010) · Nature Genetics · doi:10.1038/ng.533 · Cited by 379
Timmers, H. J. L. M., Chen, C. C., Carrasquillo, J. A., Whatley, M., Ling, A., Havekes, B., Eisenhofer, G., Martiniova, L., Adams, K. T., & Pacak, K. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1248 · Cited by 348
Self-citationTimmers, H. J. L. M., Kozupa, A., Chen, C. C., Carrasquillo, J. A., Ling, A., Eisenhofer, G., Adams, K. T., Solis, D., Lenders, J. W. M., & Pacak, K. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6297 · Cited by 340
Self-citationKaelin, W. G. (2007) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.2.010506.092049 · Cited by 336
Pheochromocytomas: Detection with18F DOPA Whole-Body PET—Initial Results
Hoegerle, S., Nitzsche, E., Altehoefer, C., Ghanem, N., Manz, T., Brink, I., Reincke, M., Moser, E., & Neumann, H. P. H. (2002) · Radiology · doi:10.1148/radiol.2222010622 · Cited by 325
Pheochromocytomas: Imaging with 2-[Fluorine-18]fluoro-2-deoxy-d-glucose PET
Shulkin, B. L., Thompson, N. W., Shapiro, B., Francis, I. R., & Sisson, J. C. (1999) · Radiology · doi:10.1148/radiology.212.1.r99jl3035 · Cited by 305
Beyond ANOVA, Basics of Applied Statistics
Amster, S. J. (1987) · Technometrics · doi:10.1080/00401706.1987.10488261 · Cited by 289
SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma
Bayley, J.-P., Kunst, H. P., Cascon, A., Sampietro, M. L., Gaal, J., Korpershoek, E., Hinojar-Gutierrez, A., Timmers, H. J., Hoefsloot, L. H., Hermsen, M. A., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70007-3 · Cited by 276
Self-citationTimmers, H. J. L. M., Kozupa, A., Eisenhofer, G., Raygada, M., Adams, K. T., Solis, D., Lenders, J. W. M., & Pacak, K. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2315 · Cited by 276
Self-citationThe Warburg effect is genetically determined in inherited pheochromocytomas
Favier, J., Brière, J.-J., Burnichon, N., Rivière, J., Vescovo, L., Benit, P., Giscos-Douriez, I., De Reyniès, A., Bertherat, J., Badoual, C., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007094 · Cited by 232
Pacak, K., Eisenhofer, G., Carrasquillo, J. A., Chen, C. C., Li, S.-T., & Goldstein, D. S. (2001) · Hypertension · doi:10.1161/01.hyp.38.1.6 · Cited by 216
Self-citationFunctional Consequences of a SDHB Gene Mutation in an Apparently Sporadic Pheochromocytoma
Gimenez-Roqueplo, A.-P., Favier, J., Rustin, P., Rieubland, C., Kerlan, V., Plouin, P.-F., Rötig, A., & Jeunemaitre, X. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020525 · Cited by 209
Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma
Eisenhofer, G., Pacak, K., Huynh, T.-T., Qin, N., Bratslavsky, G., Linehan, W. M., Mannelli, M., Friberg, P., Grebe, S. K., Timmers, H. J., et al. (2010) · Endocrine Related Cancer · doi:10.1677/erc-10-0211 · Cited by 189
Self-citationPauwels, E. K. J., Sturm, E. J. C., Bombardieri, E., Cleton, F. J., & Stokkel, M. P. M. (2000) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/pl00008465 · Cited by 169
Fiebrich, H., Brouwers, A. H., Kerstens, M. N., Pijl, M. E. J., Kema, I. P., de Jong, J. R., Jager, P. L., Elsinga, P. H., Dierckx, R., van der Wal, J. E., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1054 · Cited by 162
Phaeochromocytoma, new genes and screening strategies
Gimenez‐Roqueplo, A., Lehnert, H., Mannelli, M., Neumann, H., Opocher, G., Maher, E. R., Plouin, P., & on behalf of the European Network for the Study of Adrenal Tumours (ENS@T) Pheochromocytoma Working Group (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02714.x · Cited by 142
King, K. S., Chen, C. C., Alexopoulos, D. K., Whatley, M. A., Reynolds, J. C., Patronas, N. J., Ling, A. L., Adams, K. T., Xekouki, P., Lando, H. M., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0333 · Cited by 141
Self-citation18F-FDG Avidity of Pheochromocytomas and Paragangliomas: A New Molecular Imaging Signature?
Taïeb, D., Sebag, F. A., Barlier, A., Tessonnier, L., Palazzo, F. F., Morange, I., Niccoli, P., Fakhry, N., Micco, C. D., Cammilleri, S., et al. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.060731 · Cited by 137
Timmers, H. J. L. M., Hadi, M., Carrasquillo, J. A., et al. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.042721 · Cited by 114
Self-citationCharacterization of the normal adrenal gland with 18F-FDG PET/CT.
Bagheri, B., Maurer, A. H., Cone, L., Doss, M., & Adler, L. P. (2004) · PubMed · Cited by 82
Timmers, H. J. L. M., Eisenhofer, G., Carrasquillo, J. A., Chen, C. C., Whatley, M. A., Ling, A. L., Adams, K. T., & Pacák, K. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03496.x · Cited by 81
Self-citationMann, G. N., Link, J. M., Pham, P., Pickett, C. A., Byrd, D. R., Kinahan, P. E., Krohn, K. A., & Mankoff, D. A. (2006) · Annals of Surgical Oncology · doi:10.1245/aso.2006.04.022 · Cited by 79
18FDG PET in oncology: The best and the worst (Review)
Belhocine, T., Spaepen, K., Dusart, M., Castaigne, C., Muylle, K., Bourgeois, P., Bourgeois, D., Dierickx, L., & Flamen, P. (2006) · International Journal of Oncology · doi:10.3892/ijo.28.5.1249 · Cited by 65
Cited by
Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline
Lenders, J. W. M., Duh, Q.-Y., Eisenhofer, G., Gimenez-Roqueplo, A.-P., Grebe, S. K. G., Murad, M. H., Naruse, M., Pacak, K., & Young, W. F. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1498 · Cited by 2,827
Self-citationParaganglioma and phaeochromocytoma: from genetics to personalized medicine
Favier, J., Amar, L., & Gimenez-Roqueplo, A.-P. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.188 · Cited by 490
Taïeb, D., Hicks, R. J., Hindié, E., Guillet, B. A., Avram, A., Ghedini, P., Timmers, H. J., Scott, A. T., Elojeimy, S., Rubello, D., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04398-1 · Cited by 403
Self-citationNew Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification
Crona, J., Taïeb, D., & Pacak, K. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00062 · Cited by 324
Self-citationJanssen, I., Blanchet, E. M., Adams, K., Chen, C. C., Millo, C. M., Herscovitch, P., Taieb, D., Kebebew, E., Lehnert, H., Fojo, A. T., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2751 · Cited by 276
Self-citation
Metadata
- Authors
- Timmers, H. J. L. M., Chen, C. C., Carrasquillo, J. A., Whatley, M., Ling, A., Eisenhofer, G., King, K. S., Rao, J. U., Wesley, R. A., Adams, K. T., & Pacak, K.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-04-18
- Volume
- 104
- Issue
- 9
- Pages
- 700-708
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2150962314
- Cited by
- 283
- References
- 31
- FWCI
- 25.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.